Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Heron Therapeutics, Inc. (Heron Therapeutics or the Company) (NASDAQ: HRTX) securities between October 31, 2018 and April 30, 2019, inclusive (the Class Period). Heron Therapeutics investors have until August 5, 2019 to file a lead plaintiff motion.
Investors suffering losses on their Heron Therapeutics investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected].
On May 1, 2019, the Company confirmed receipt of a Complete Response Letter from the FDA in which the FDA was unable to approve the Companys New Drug Application for a new postoperative pain medication it had been developing, due to the need for additional information.
On this news, shares of Heron Therapeutics fell $3.93 per share, or over 18%, to close at $17.75 on May 1, 2019, thereby injuring investors.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) the Company had failed to include adequate Chemistry, Manufacturing, and Controls and non-clinical information in its New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for HTX-011; (2) the foregoing increased the likelihood that the FDA would not approve the Companys NDA for HTX-011; and (3) as a result, defendants public statements were materially false and/or misleading at all relevant times.
If you purchased shares of Heron Therapeutics, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.